CeriBell (NASDAQ:CBLL) Stock Price Down 2.9% After Insider Selling

CeriBell (NASDAQ:CBLL - Get Free Report) fell 2.9% on Tuesday after an insider sold shares in the company. The company traded as low as $14.52 and last traded at $14.50. 15,279 shares were traded during mid-day trading, a decline of 94% from the average session volume of 267,340 shares. The stock had previously closed at $14.93.

Specifically, CEO Xingjuan Chao sold 5,700 shares of CeriBell stock in a transaction dated Thursday, April 17th. The shares were sold at an average price of $15.02, for a total value of $85,614.00. Following the completion of the sale, the chief executive officer now owns 746,451 shares in the company, valued at $11,211,694.02. The trade was a 0.76 % decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. Also, CEO Xingjuan Chao sold 3,372 shares of the stock in a transaction that occurred on Monday, April 21st. The stock was sold at an average price of $15.03, for a total transaction of $50,681.16. Following the transaction, the chief executive officer now owns 743,079 shares in the company, valued at approximately $11,168,477.37. The trade was a 0.45 % decrease in their position. The disclosure for this sale can be found here.

Analyst Upgrades and Downgrades

A number of research firms have recently weighed in on CBLL. Canaccord Genuity Group reiterated a "buy" rating and set a $33.00 target price on shares of CeriBell in a research report on Wednesday, February 26th. LADENBURG THALM/SH SH began coverage on shares of CeriBell in a research report on Friday, April 4th. They set a "buy" rating and a $32.00 price objective for the company. Seven analysts have rated the stock with a buy rating, According to data from MarketBeat.com, CeriBell has an average rating of "Buy" and an average target price of $32.50.

CeriBell Stock Down 1.2 %

The stock's 50 day moving average price is $19.64.

CeriBell (NASDAQ:CBLL - Get Free Report) last released its quarterly earnings data on Tuesday, February 25th. The company reported ($0.40) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.32) by ($0.08). The company had revenue of $18.53 million for the quarter, compared to analyst estimates of $17.55 million. Equities research analysts predict that CeriBell will post -2.46 EPS for the current fiscal year.

Hedge Funds Weigh In On CeriBell

Several large investors have recently bought and sold shares of CBLL. FMR LLC bought a new stake in shares of CeriBell during the fourth quarter worth about $128,120,000. TPG GP A LLC acquired a new position in CeriBell in the 4th quarter valued at approximately $102,677,000. Red Tree Management LLC bought a new position in shares of CeriBell during the fourth quarter valued at $57,083,000. Yu Fan bought a new stake in shares of CeriBell in the fourth quarter worth $31,631,000. Finally, ABG WTT Global Life Science Capital Partners GP Ltd bought a new position in CeriBell during the 4th quarter worth $28,160,000.

CeriBell Company Profile

We are a commercial-stage medical technology company focused on transforming the diagnosis and management of patients with serious neurological conditions. We have developed the Ceribell System, a novel, point-of-care electroencephalography (“EEG”) platform specifically designed to address the unmet needs of patients in the acute care setting.